NNVC - NanoViricides, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.7950
+0.0150 (+1.9231%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.7800
Open0.7965
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7800 - 0.8000
52 Week Range0.7200 - 1.6400
Volume65,111
Avg. Volume132,995
Market Cap50.382M
Beta-0.37
PE Ratio (TTM)N/A
EPS (TTM)-0.1700
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
Trade prices are not sourced from all markets
  • NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today
    PR Newswire12 days ago

    NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today

    SHELTON, Conn., April 9, 2018 /PRNewswire/ -- NanoViricides, Inc. (the "Company") reports that its drug candidates in the HerpeCide™ program have been found to be safe based on multiple parameters in the recently completed initial non-GLP safety/toxicology study. No clinically observable adverse safety and toxicology effects were seen in this study of the Company's optimized topical dermal drug candidates. The drug candidates tested in this safety/toxicology study have previously shown broad-spectrum effectiveness against alphaherpesviruses, i.e.

  • NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin
    PR Newswirelast month

    NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin

    SHELTON, Conn., March 19, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") has announced that it has expanded its in vivo testing agreement with the University of Wisconsin to encompass testing its topical anti-herpes agents in animal models of HSV-induced dermal, ocular and genital herpes virus infections. NanoViricides has previously reported excellent effectiveness of its earlier drug candidates in the HerpeCide™ program against the highly pathogenic, neurotropic strain of HSV-1, namely H129, leading to full survival of lethally infected mice. Since then, the Company has further improved these candidates.  The resulting drug candidates have shown excellent efficacy in cell cultures against HSV-1, HSV-2, as well as VZV (aka the chickenpox virus, which is also the cause of shingles).

  • Is NanoViricides Inc’s (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers?
    Simply Wall St.2 months ago

    Is NanoViricides Inc’s (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers?

    Eugene Seymour took the helm as NanoViricides Inc’s (AMEX:NNVC) CEO and grew market cap to US$58.43M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial part ofRead More...

  • ACCESSWIRE2 months ago

    Blog Exposure - Shire Gets BLA and Priority Review Status from FDA for Lanadelumab for the Prevention of HAE Attacks

    Stock Monitor: NanoViricides Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 26, 2018 / Active-Investors.com has just released a free research report on Shire PLC (NASDAQ: SHPG ). If you want ...

  • Associated Press2 months ago

    NanoViricides reports 2Q loss

    On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 4 cents. Losses, adjusted to extinguish debt, were 2 cents per share. The company's shares closed at 97 cents. A year ...

  • NanoViricides Files Quarterly Report for Period Ending December 31, 2017
    PR Newswire2 months ago

    NanoViricides Files Quarterly Report for Period Ending December 31, 2017

    SHELTON, Conn., Feb. 21, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its second quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission on Tuesday, February 20, 2018. The Company reported that it had approximately $12.0 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of December 31, 2017, the end of the reporting period. The Company's research and development (R&D) expenditure of approximately $1.4M in the current quarter was in line with our budgeted estimates.

  • How Does NanoViricides Inc (NYSEMKT:NNVC) Affect Your Portfolio Returns?
    Simply Wall St.2 months ago

    How Does NanoViricides Inc (NYSEMKT:NNVC) Affect Your Portfolio Returns?

    For NanoViricides Inc’s (AMEX:NNVC) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measures NNVC’sRead More...

  • Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)?
    Simply Wall St.2 months ago

    Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)?

    In this article, I’m going to take a look at NanoViricides Inc’s (AMEX:NNVC) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
    PR Newswire4 months ago

    Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

    SHELTON, Conn. , Dec. 6, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® ...

  • Is NanoViricides Inc (NNVC) A Financially Sound Company?
    Simply Wall St.5 months ago

    Is NanoViricides Inc (NNVC) A Financially Sound Company?

    While small-cap stocks, such as NanoViricides Inc (AMEX:NNVC) with its market cap of USD $63.34M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • NanoViricides Files Quarterly Report for Period Ending September 30, 2017
    PR Newswire5 months ago

    NanoViricides Files Quarterly Report for Period Ending September 30, 2017

    SHELTON, Conn., Nov. 20, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its first quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission on Tuesday, November 14, 2017. NanoViricides reported that it had approximately $13.7 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of September 30, 2017, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $1.56 M. The Company's research and development (R&D) expenditure have decreased for the quarter but are in line with our budgeted estimates.

  • ACCESSWIRE5 months ago

    NanoViricides Signs Extension of Herpes Virus (HSV) Testing Agreement with University of Wisconsin

    SHELTON, CT / ACCESSWIRE / November 8, 2017 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") has announced that it has extended and expanded its in vivo testing agreement with researchers ...

  • NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
    PR Newswire5 months ago

    NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

    SHELTON, Conn., Nov. 6, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") reports that Dr. Vivien Boniuk, Consultant in Ophthalmology at the Company, will present the successful results of certain anti-herpes nanoviricide treatments for Viral Acute Retinal Necrosis (v-ARN) at the 2017 Annual meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology to be held in New Orleans, LA. The same lead candidates that the Company has previously found to be highly effective against VZV in the shingles human skin patch model in Professor Moffat's Lab at SUNY Upstate Medical Center were evaluated for efficacy in this v-ARN mouse model study.

  • Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
    PR Newswire6 months ago

    Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center

    The Company will conduct additional studies in order to finalize the candidates for clinical drug development, and to obtain IND-enabling pre-clinical data, under the extension. The final candidate is expected to undergo toxicology and safety studies leading to IND submission to the FDA for the treatment of shingles in humans.

  • NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
    PR Newswire6 months ago

    NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology

    SHELTON, Conn., Oct. 17, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") will present the results of its anti-herpes nanoviricide treatment for Viral Acute Retinal Necrosis (vARN) at the 2017 Annual meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology to be held in New Orleans, LA. The abstract of the study has been accepted for presentation at this OMIG meeting on November 10th, 2017.  Dr. Vivien Boniuk, consultant in ophthalmology at NanoViricides, Inc. will make the scientific presentation.  The presentation will cover both the inhibition of virus infection and prevention of ocular tissue damage following virus infection.

  • NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
    PR Newswire7 months ago

    NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

    SHELTON, Conn., Sept. 29, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Thursday, September 28, 2017 in a timely manner. NanoViricides, Inc. is a global leader in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle.

  • NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017
    PR Newswire7 months ago

    NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017

    SHELTON, Conn., Sept. 11, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE "NNVC") today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
    PR Newswire9 months ago

    NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin

    SHELTON, Conn., July 10, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its anti-shingles nanoviricides® drug candidates achieved dramatic reduction in infection of human skin by the varicella-zoster virus (VZV), the shingles virus. The antiviral effect of certain nanoviricide drug candidates was substantially greater than the effect of the standard positive control of cidofovir added into media.

  • NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology
    PR Newswire10 months ago

    NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology

    SHELTON, Conn., June 26, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its poster entitled "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" will be presented today at the 36th Annual Meeting of the American Society of Virology (ASV). Dr. Brian Friedrich, Senior Virologist of the Company, is presenting the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3) in this poster.

  • NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology
    PR Newswire10 months ago

    NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology

    SHELTON, Conn., June 20, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its late-breaking abstract submission has been accepted for a poster presentation at the 36th Annual Meeting of the American Society of Virology (ASV). The ASV Meeting will be hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 (https://extensionconferencecenters.uwex.edu/asv2017/). Dr. Brian Friedrich, Senior Virologist of the Company, will present the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3).

  • NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City
    PR Newswire10 months ago

    NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City

    SHELTON, Conn., June 13, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its CEO, Eugene Seymour, MD, MPH., will describe the Company's progress towards human clinical trials stage at the 2017 Marcum Investor Conference. The Company has recently reported that its drug candidates for topical treatment of shingles were almost five times more effective compared to acyclovir in cell culture studies.

  • NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
    PR Newswire10 months ago

    NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies

    SHELTON, Conn., June 6, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its topical drug candidates in development for the treatment of shingles have demonstrated excellent inhibition of the causative virus with practically no cytotoxicity in cell culture assays using multiple cell lines. Two of the nanoviricide drug candidates in the HerpeCide™ program demonstrated almost complete inhibition of the varicella-zoster virus (VZV) at the highest drug doses, whereas acyclovir at the same drug dose exhibited partial inhibition of the virus.

  • Associated Press11 months ago

    NanoViricides reports 3Q loss

    On a per-share basis, the West Haven, Connecticut-based company said it had a loss of 5 cents. The company's shares closed at $1.24. A year ago, they were trading at $1.55. _____ This story was generated ...

  • NanoViricides Files Quarterly Report for Period Ending 2017-03-31
    PR Newswire11 months ago

    NanoViricides Files Quarterly Report for Period Ending 2017-03-31

    SHELTON, Conn., May 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed the quarterly report for its third quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Monday, May 15th. NanoViricides reported that it had approximately $16.74 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of March 31, 2017, the end of the reporting period. Briefly, holders of $5,000,000 principal value Series B Convertible Debentures, namely, an entity controlled by Dr. Milton Boniuk, a director of the Company, and The Boniuk Charitable Foundation, converted $5,000,000 of Series B debentures into equity, and the remaining $1,000,000 principal, with accrued interest as of the maturity date, was repaid to the holders thereof in cash, on or about.

  • NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles
    PR Newswirelast year

    NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

    SHELTON, Conn., April 26, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel. NanoViricides, Inc. is a global leader developing antiviral nanomedicines for the treatment of a number of different viral infections. The Company is currently focused on developing its broad spectrum anti-herpesvirus drug candidates.